This second round of funding raises the equivalent of $45.4 million to support the advancement of Oxford-based Evox’s exosome-based therapeutics pipeline, including pushing several rare disease ...

Evox Therapeutics, a privately held biotechnology ... The company’s internal exosome pipeline is focused on rare, life-threatening diseases with significant unmet need. Its lead product is ...

Eli Lilly has announced a central nervous system research tie-up with UK biotech Evox Therapeutics, which focuses on drug engineering using vesicles to deliver drugs to targets. These tiny ...